Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience

…, P Perros, C Neoh, AJ Dickinson… - European Journal of …, 2003 - academic.oup.com
To improve management of patients with Graves' orbitopathy, a multi-center collaborative
approach is necessary in order to have large enough sample sizes for meaningful randomized …

Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey

…, L Baldeschi, K Boboridis, AJ Dickinson… - British Journal of …, 2007 - bjo.bmj.com
Background: This study was performed to determine clinical features of dysthyroid optic
neuropathy (DON) across Europe. Methods: Forty seven patients with DON presented to seven …

Controversies in the clinical evaluation of active thyroid‐associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment

AJ Dickinson, P Perros - Clinical endocrinology, 2001 - Wiley Online Library
Despite many learned publications over recent decades, the assessment of active thyroid‐associated
orbitopathy (TAO) remains difficult and controversial. There are no biochemical, …

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer …

…, C Dayan, C Daumerie, AJ Dickinson… - The Lancet Diabetes & …, 2018 - thelancet.com
Background European guidelines recommend intravenous methylprednisolone as first-line
treatment for active and severe Graves' orbitopathy; however, it is common for patients to …

The effect of B cell depletion therapy on anti‐TSH receptor antibodies and clinical outcome in glucocorticoid‐refractory Graves' orbitopathy

…, K Johnson, C Neoh, AJ Dickinson… - Clinical …, 2013 - Wiley Online Library
Objective This case series documents the response of nine individuals with glucocorticoid‐refractory
Graves' orbitopathy ( GO ) to B cell depletion therapy with rituximab ( RTX ). Context …

Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy

AJ Dickinson, B Vaidya, M Miller… - The Journal of …, 2004 - academic.oup.com
Several uncontrolled studies suggest octreotide is beneficial in thyroid-associated
ophthalmopathy (TAO); however, the natural tendency of TAO to improve mandates randomized, …

[HTML][HTML] Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways

P Perros, CM Dayan, AJ Dickinson, D Ezra… - Clinical …, 2015 - ncbi.nlm.nih.gov
Graves’ orbitopathy (GO) is uncommon, but responsible for considerable morbidity. A
coordinated approach between healthcare professionals is required in order to meet the needs of …

Clinical manifestations

AJ Dickinson, C Hintschich - Graves' Orbitopathy, 2017 - karger.com
Only about 5% of patients report visual symptoms such as alteration in colour perception or
blurring of vision, which may be either patchy or generalized [4, 5, 11]. These visual …

Periocular basal cell carcinoma: 5-year outcome following Slow Mohs surgery with formalin-fixed paraffin-embedded sections and delayed closure

DS Morris, E Elzaridi, L Clarke, AJ Dickinson… - British journal of …, 2009 - bjo.bmj.com
Aim: The aim of the study was to determine the 5-year outcome of periocular basal cell
carcinoma (BCC) managed by Mohs surgery using formalin-fixed, paraffin-embedded sections (…

Parameters predicting outcomes of strabismus surgery in the management of Graves' ophthalmopathy

MM Nassar, AJ Dickinson, C Neoh, C Powell… - Journal of American …, 2009 - Elsevier
BACKGROUND: Ocular dysmotility is a common feature of Graves' ophthalmopathy and
frequently requires strabismus surgery. We reviewed the short-term results of strabismus …